ArticleJournal of virology2026
N-linked glycosylation sites with low occupancy support sustained circulation of the A(H3N2) influenza A virus in the human population.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glycosylation of the influenza A virus hemagglutinin is crucial for viral fitness and immune evasion. The hemagglutinin of contemporary human A(H3N2) influenza A viruses is extensively glycosylated with up to 13 putative glycosylation sites. Glycan types and occupancy of these sites are not uniform: while most are nearly completely occupied by glycans, some, such as those at amino acid residues 45 and 144, are only partially occupied and are evolutionarily unstable. While the effects of highly occupied glycosylated sites of hemagglutinin on A(H3N2) influenza A virus biology are well studied, there is limited information on the functional impact of the low-occupancy glycosylation sites on the viral hemagglutinin. Here, by using reverse-genetics A(H3N2) influenza A viruses lacking glycans at either residue 45 or 144, or both in hemagglutinin, we demonstrate that, despite reduced receptor binding, thermal stability, and fusion, the presence of a low level of glycosylation at these positions does not impact virus growth in Madin-Darby canine kidney epithelial cell culture. In contrast, these low-occupancy sites do affect immune responses in mice, by reducing titers of antibodies that correlate with virus neutralization and protection against influenza disease. We suggest that the temporary introduction of sites with low glycosylation allows influenza viruses to reduce the immune pressure on antigenic and receptor binding sites of hemagglutinin without significantly compromising viral virulence. This mechanism may help support the sustained circulation of A(H3N2) influenza A virus in human populations. IMPORTANCE: Many of the glycosylation sites on the hemagglutinin of influenza A viruses are near antigenic sites, such that the glycans block antibody recognition and help evade population immunity. However, glycans may also reduce viral replication and virulence. Glycosylation sites at amino acid residues 45 and 144 of the hemagglutinin of contemporary A(H3N2) influenza A viruses are minimally occupied, with fewer than 10% of the sites containing glycans. This is still sufficient to partially evade antibody-based population immunity, while minimizing the impact on replication and virulence. Over time, A(H3N2) viruses have used both these sites only during limited periods, suggesting that even a low level of glycan occupancy may confer some negative selection pressure that is compensated by evasion of human population immunity. Data from this study provide a better understanding of the mechanisms that allow viruses to evade antibody-based immunity and maintain circulation in the human population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.